Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Created in March 2020 to assist policymakers to make use of existing evidence in mathematical and epidemiological models to inform strategies for minimising the impact of COVID-19, the CoMo Consortium brings together mathematical modellers, epidemiologists, health economists and public health experts from more than 40 countries across Africa, Asia and South and North America.

The COVID-19 International Modelling Consortium (CoMo Consortium) - image of he world highlighting countries with CoMo members, its logo and the text CoMo Consortium

The CoMo Consortium is delighted to have been awarded funding by the University’s COVID-19 Research Response Fund, enabling the group to continue to support country members, predominantly low- and middle-income countries, who require modelling support for non-pharmaceutical interventions such as social distancing, mask wearing and handwashing, while they wait for vaccines and to support these countries with modelling the implementation of vaccine programmes.

CoMo uses an innovative participatory approach, leveraging experts from the University of Oxford and other collaborating partners to provide capacity building and support to in-country modellers.

Lisa J. White, Professor of Modelling and Epidemiology at the University of Oxford and Director of the CoMo Consortium, explains:

 “Our approach in the CoMo Consortium represents a new more equitable way to conduct pandemic modelling. Here, experts within the country teams take the leading role in modelling the pandemic working closely with national policymakers. Researchers at Oxford provide technical and consultative support as needed. Modelling work is carried out within the health and policy context of each country leading to rapid uptake of results via continuous communication with the decisionmakers.”

This approach has enabled in-country teams to assist policymakers in making evidence-based decisions to contain the spread of COVID-19, supported by epidemiological and economic models adapted to each country’s context. In addition to this the group has published a series of papers which are now published.

For more information, visit our BMJ co-hosted website

Similar stories

Systematic review identifies research gaps for Chagas disease

A new, large-scale systematic review published in PLOS Neglected Tropical Diseases has identified clear, significant research gaps in the diagnosis and treatment of Chagas disease. The paper also highlights significant differences in study design, diagnostic methods, duration of follow-up, and the timing of outcome assessment used by investigators even in the last decade.

The scale of the problem of visceral leishmaniasis in pregnancy is underestimated

Despite the limitations and paucity of data, the most comprehensive review of visceral leishmaniasis to date in pregnant women and vertical transmission of leishmaniasis has confirmed that liposomal amphotericin B is the safest treatment option and it is critical to ensure access to this.

RECOVERY Trial announced as overall winner of Best COVID-19 Response Project Award in the UK

The RECOVERY Trial has won the Project Management Institute’s Special Covid-19 UK Response Project Award. The award specifically recognised RECOVERY’s work to investigate whether the cheap steroid dexamethasone was an effective treatment for patients hospitalised with severe COVID-19.

ISARIC COVID-19 clinical database passes ½ million patient records mark

COVID-19 has exposed our vulnerability to pandemic infections and shown what works, and what does not. It has tested the effectiveness of the Oxford-based global, open-source, collaborative approach set up 10 years ago to prevent illness and deaths from infectious disease outbreaks: ISARIC, the International Severe Acute Respiratory and Emerging Infection Consortium.

RECOVERY Trial named joint winner of HDR UK’s Impact of the Year Award

The RECOVERY trial has been jointly awarded Health Data Research UK’s 2021 Impact of the Year Award. This award is open to projects which had effectively used health data to improve people’s lives, including through clinical practice, policy, software, algorithms, or publications. The award was presented by James O’Shaughnessy at HDR UK’s online Annual Scientific Conference: Data Insights in a Pandemic.

OUCRU scientists identify combination of biological markers associated with severe dengue

Nguyen Lam Vuong, Sophie Yacoub & colleagues have identified a combination of biological markers in patients with dengue that could predict whether they go on to develop moderate to severe disease. Biomarkers are used to identify the state or risk of a disease in patients; these findings could aid the development of biomarker panels for clinical use and help improve triage and risk prediction in patients with dengue.